Polycythaemia vera and essential thrombocythaemia in the elderly

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Essential thrombocythaemia (ET) and polycythaemia vera (PV) are chronic myeloproliferative disorders originating from hematopoietic stem cells.
• Both conditions carry risks of thrombotic events, myelofibrosis, and leukaemic conversion, particularly PV.
• A lack of randomized clinical trials hinders evidence-based therapeutic decision-making.

Purpose of the Study:

• To review the diagnosis, clinical manifestations, epidemiology, and treatment options for ET and PV.
• To emphasize treatment efficacy and therapy-related leukaemic risk in managing these disorders.
• To discuss risk stratification for thrombosis in ET and PV patients.

Main Methods:

• Review of existing literature on Essential Thrombocythaemia and Polycythaemia Vera.
• Analysis of risk factors for thrombosis, myelofibrosis, and leukaemic transformation.
• Evaluation of current treatment strategies and their efficacy.

Main Results:

• Risk stratification into low and high-risk groups for thrombosis is crucial for management.
• Treatment goals include reducing thrombotic risk and preventing disease progression.
• Therapeutic choices must consider the potential for therapy-related leukaemic risk.

Conclusions:

• Optimal management of ET and PV requires careful risk assessment and consideration of treatment efficacy.
• Further research and randomized clinical trials are needed to establish definitive therapeutic guidelines.
• Balancing the benefits of thrombosis prevention with the risks of treatment is essential.